The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience.
Marc Ryan Matrana
No relevant relationships to disclose
Aditya V. Shetty
No relevant relationships to disclose
Bradley J. Atkinson
No relevant relationships to disclose
Lianchun Xiao
No relevant relationships to disclose
Paul G. Corn
No relevant relationships to disclose
Randall E. Millikan
No relevant relationships to disclose
Eric Jonasch
No relevant relationships to disclose
Nizar M. Tannir
No relevant relationships to disclose